RayThera is a clinical-stage-bound biotech applying AI and computational chemistry to small-molecule drug discovery for immunological and inflammatory diseases. The company aims to develop safer and more effective therapeutics by using machine learning to design and prioritize candidates against validated immunology targets, then advancing its lead programs into and through Phase I clinical testing. By integrating AI-driven design with traditional medicinal chemistry and biology, RayThera seeks to improve the efficiency and quality of its pipeline relative to conventional discovery. In April 2025 it completed an oversubscribed Series A financing totaling $110M to fund advancement of its lead candidates into the clinic, signaling strong investor conviction in its AI-enabled immunology approach.